Oxidative stress and androgen receptor expression in castration-resistant prostate cancer

Nishinihon Journal of Urology

Volumn 72, Issue 3, 2010, Pages 97-102

  Shiota, Masaki ^a   Yokomizo, Akira ^a   Tada, Yasuhiro ^a   Inokuchi, Junichi ^a   Naito, Seiji ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Androgen deprivation therapy; Androgen receptor; Castration resistant prostate cancer; Reactive oxygen species; Twist1

Indexed keywords

EID: 77951168498     PISSN: 00290726     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Debes, J. D. and Tindall, D. J.: The role of androgens and the androgen receptor in prostate cancer. Cancer Lett. 187: 1-7, 2002.
2. Shiota, M. et al. : Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twistl and androgen receptor overexpression. Oncogene 29: 237-250, 2010.
3. Attar, R. M. et al. : Castration-resistant prostate cancer: locking up the molecular escape.routes. Clin. Cancer Res. 15: 3251-3255, 2009.
4. Linja, M. J. et al. : Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 61: 3550-3555, 2001.
5. Taplin, M. E. et al.: Androgen receptor mutations in androgen-independent prostate cancer: cancer and leukemia group B study 9663. J. Clin. Oncol. 21: 2673-2678, 2003.
6. Dehm, S. M. et al. : Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 68: 5469-5477, 2008.
7. Hu, R. et al. : Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 69: 16-22, 2009.
8. Culig, Z. et al.: Expression and function of androgen receptor coactivators in prostate cancer. J. Steroid Biochem. Mol. Biol. 92: 265-271, 2004.
9. Stanbrough, M. et al.: Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 66: 2815-2825. 2006.
10. Montgomery, R. B. et al.: Maintenance of intra- tumoral androgens in metastatic prostate cancer : a mechanism for castration-resistant tumor growth. Cancer Res. 68: 4447-4454, 2008.
11. Locke, J. A. et al. : Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 68: 6407-6415, 2008.
12. Culig, Z. et al. : Androgen receptor activation in prostate tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 54: 5474-5478, 1994.
13. Craft N. et al. : A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med. 5: 280-285, 1999.
14. Hobisch, A. et al. : Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res. 58: 4640-4645, 1998.
15. Tamura, K. et al.: Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res. 67: 5117-5125, 2007.
16. Olson, E. N. and Klein, W. H.: bHLH factors in muscle development : dead lines and commitments, what to leave in and what to leave out Genes Dev. 8: 1-8. 1994.
17. Lee, T. K. et al. : Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin. Cancer Res. 12: 5369-5376. 2006.
18. Shiota, M. et al.: Twist promotes tumor cell growth through YB-I expression. Cancer Res. 68 : 98-105. 2008.
19. Yang, J. et al.: Twist a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117: 927-939, 2004.
20. Wang, X. et al. : Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells. Oncogene 23: 474-482, 2004.
21. Zhou, W. L. et al. : Short interfering RNA directed against TWIST, a novel zinc finger transcription factor, increases A549 cell sensitivity to cisplatin via MAPK/mitochondrial pathway. Biochem. Biophys. Res. Commun. 369: 1098-1102, 2008.
22. Zheng, Z. et al. : Significance of TWIST expression and its association with E-cadherin in bladder cancer. Hum. Path. 38: 598-606, 2007.
23. Kwok, W. K. et al. : Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target Cancer Res. 65: 5153-5162, 2005.
24. Kohno, K. et al. : The pleiotrophic functions of the Y-box-binding protein, YB-1. Bioessays 25: 691-698, 2003.
25. Kuwano, M. et al.: The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. MoL Cancer Ther. 3: 1485-1492. 2004.
26. Giménez-Bonafé, P. et al.: YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate 59: 337-349. 2004.
27. Shiota, M. et al.: Twist and p53 reciprocally regulate target genes via direct interaction. Oncogene 27: 5543-5553, 2008.
28. Shiota, M. et al. : Programmed cell death protein 4 down-regulates Y-box binding protein-1 expression via a direct interaction with Twistl to suppress cancer cell growth. Cancer Res. 69: 3148-3156, 2009.
29. Yang, M. H. et al. : Direct regulation of TWIST by HIF-I α promotes metastasis. Nat Cell. Biol. 10 : 295-305, 2008.
30. Bostwick, D. G. et al.: Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer. Cancer 89: 123-134.2000.
31. Hakimian, P. et al. : Metabolic and cardiovascular effects of androgen deprivation therapy. BJU Int 102: 1509-1514, 2008.